[{"edinetCode":"E00974","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2408.0,"averageTemporaryStaff":566.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":10338000.0,"sharesOwendPercent":0.602,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":4568.97,"equityRatio":0.454,"cashAndCashEquivalents":7112000000.0,"assets":165247000000.0,"currentAssets":86552000000.0,"fixedAsset":78695000000.0,"tangibleFixedAssets":74904000000.0,"intangibleFixedAssets":1894000000.0,"investmentAndOtherAssets":1895000000.0,"liabilities":90302000000.0,"currentLiabilities":34601000000.0,"shorTermDept":1740000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":2681000000.0,"fixedLiabilities":55701000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":39253000000.0,"netAsset":74945000000.0,"capitalStock":74827000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":67879000000.0,"treasuryStock":-5639000000.0,"valuationAndConversionAdjustments":117000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":84949000000.0,"costOfSales":45902000000.0,"grossProfit":39046000000.0,"sgaExpenses":32176000000.0,"salaryAndBenefit":9219000000.0,"depreciationAndSGA":null,"RDExpenses":9352000000.0,"operatingIncome":6869000000.0,"nonOperatingIncome":1307000000.0,"nonOperatingExpenses":760000000.0,"interestExpense":164000000.0,"ordinaryProfit":7417000000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":180000000.0,"incomeBeforeTax":7237000000.0,"incomeTaxes":1661000000.0,"netIncome":5576000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":5576000000.0,"comprehensiveIncome":5858000000.0,"eps":339.96,"dilutedEps":314.23,"dividendPerShare":null,"per":16.56,"roe":0.077,"cashFlowFromOperatingActivities":10195000000.0,"depreciationAndCashflowFromOperatingActivities":7980000000.0,"cashFlowFromInvestingActivities":-22206000000.0,"cashFlowFromFinancialActivities":-92000000.0,"changesInCashAndCashEquivalents":-11414000000.0,"列1":"asr","submitDate":"2017\/6\/28","stockCode":4553,"accountingYear":"第61期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2449.0,"averageTemporaryStaff":635.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":9870000.0,"sharesOwendPercent":0.6014,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":4872.28,"equityRatio":0.451,"cashAndCashEquivalents":11511000000.0,"assets":177325000000.0,"currentAssets":95377000000.0,"fixedAsset":81947000000.0,"tangibleFixedAssets":76989000000.0,"intangibleFixedAssets":1936000000.0,"investmentAndOtherAssets":3021000000.0,"liabilities":97405000000.0,"currentLiabilities":35904000000.0,"shorTermDept":850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":4249000000.0,"fixedLiabilities":61501000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":44803000000.0,"netAsset":79920000000.0,"capitalStock":79765000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":72816000000.0,"treasuryStock":-5639000000.0,"valuationAndConversionAdjustments":155000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":93430000000.0,"costOfSales":50379000000.0,"grossProfit":43050000000.0,"sgaExpenses":31407000000.0,"salaryAndBenefit":9513000000.0,"depreciationAndSGA":null,"RDExpenses":7725000000.0,"operatingIncome":11643000000.0,"nonOperatingIncome":1632000000.0,"nonOperatingExpenses":1557000000.0,"interestExpense":158000000.0,"ordinaryProfit":11717000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":1883000000.0,"incomeBeforeTax":9833000000.0,"incomeTaxes":3338000000.0,"netIncome":6495000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6495000000.0,"comprehensiveIncome":6533000000.0,"eps":395.99,"dilutedEps":366.08,"dividendPerShare":null,"per":16.79,"roe":0.084,"cashFlowFromOperatingActivities":19230000000.0,"depreciationAndCashflowFromOperatingActivities":8173000000.0,"cashFlowFromInvestingActivities":-20093000000.0,"cashFlowFromFinancialActivities":4670000000.0,"changesInCashAndCashEquivalents":4399000000.0,"列1":"asr","submitDate":"2018\/6\/27","stockCode":4553,"accountingYear":"第62期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2472.0,"averageTemporaryStaff":643.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":9912000.0,"sharesOwendPercent":0.6043,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":1864.92,"equityRatio":0.486,"cashAndCashEquivalents":26652000000.0,"assets":188803000000.0,"currentAssets":108206000000.0,"fixedAsset":80597000000.0,"tangibleFixedAssets":73663000000.0,"intangibleFixedAssets":1470000000.0,"investmentAndOtherAssets":5463000000.0,"liabilities":97032000000.0,"currentLiabilities":37177000000.0,"shorTermDept":850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6396000000.0,"fixedLiabilities":59854000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":43407000000.0,"netAsset":91771000000.0,"capitalStock":91682000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":84734000000.0,"treasuryStock":-5640000000.0,"valuationAndConversionAdjustments":88000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":105104000000.0,"costOfSales":56705000000.0,"grossProfit":48399000000.0,"sgaExpenses":32431000000.0,"salaryAndBenefit":9935000000.0,"depreciationAndSGA":null,"RDExpenses":7916000000.0,"operatingIncome":15968000000.0,"nonOperatingIncome":3234000000.0,"nonOperatingExpenses":337000000.0,"interestExpense":146000000.0,"ordinaryProfit":18865000000.0,"extraordinaryGain":300000000.0,"extraordinaryLoss":279000000.0,"incomeBeforeTax":18886000000.0,"incomeTaxes":5410000000.0,"netIncome":13475000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":13475000000.0,"comprehensiveIncome":13409000000.0,"eps":273.85,"dilutedEps":253.32,"dividendPerShare":null,"per":10.64,"roe":0.157,"cashFlowFromOperatingActivities":19002000000.0,"depreciationAndCashflowFromOperatingActivities":8340000000.0,"cashFlowFromInvestingActivities":-3994000000.0,"cashFlowFromFinancialActivities":-809000000.0,"changesInCashAndCashEquivalents":15141000000.0,"列1":"asr","submitDate":"2019\/6\/26","stockCode":4553,"accountingYear":"第63期（自　2018年4月1日　至　2019年3月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.501,"cashAndCashEquivalents":null,"assets":188860000000.0,"currentAssets":107577000000.0,"fixedAsset":81282000000.0,"tangibleFixedAssets":73096000000.0,"intangibleFixedAssets":1362000000.0,"investmentAndOtherAssets":6823000000.0,"liabilities":94291000000.0,"currentLiabilities":35953000000.0,"shorTermDept":1200000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6554000000.0,"fixedLiabilities":58337000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":41926000000.0,"netAsset":94568000000.0,"capitalStock":94463000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":87514000000.0,"treasuryStock":-5640000000.0,"valuationAndConversionAdjustments":105000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":28406000000.0,"costOfSales":15099000000.0,"grossProfit":13306000000.0,"sgaExpenses":8097000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":5209000000.0,"nonOperatingIncome":137000000.0,"nonOperatingExpenses":63000000.0,"interestExpense":33000000.0,"ordinaryProfit":5283000000.0,"extraordinaryGain":null,"extraordinaryLoss":0.0,"incomeBeforeTax":5283000000.0,"incomeTaxes":1518000000.0,"netIncome":3764000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3764000000.0,"comprehensiveIncome":3781000000.0,"eps":76.51,"dilutedEps":70.77,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4553,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":28905000.0,"sharesOwendPercent":0.5873,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.509,"cashAndCashEquivalents":31104000000.0,"assets":192305000000.0,"currentAssets":110952000000.0,"fixedAsset":81353000000.0,"tangibleFixedAssets":72637000000.0,"intangibleFixedAssets":1248000000.0,"investmentAndOtherAssets":7467000000.0,"liabilities":94442000000.0,"currentLiabilities":37892000000.0,"shorTermDept":950000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6562000000.0,"fixedLiabilities":56549000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":40133000000.0,"netAsset":97863000000.0,"capitalStock":97764000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":90816000000.0,"treasuryStock":-5640000000.0,"valuationAndConversionAdjustments":98000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":55350000000.0,"costOfSales":29217000000.0,"grossProfit":26132000000.0,"sgaExpenses":16913000000.0,"salaryAndBenefit":5038000000.0,"depreciationAndSGA":null,"RDExpenses":4346000000.0,"operatingIncome":9218000000.0,"nonOperatingIncome":597000000.0,"nonOperatingExpenses":78000000.0,"interestExpense":69000000.0,"ordinaryProfit":9738000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":0.0,"incomeBeforeTax":9738000000.0,"incomeTaxes":2671000000.0,"netIncome":7066000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":7066000000.0,"comprehensiveIncome":7076000000.0,"eps":143.6,"dilutedEps":132.82,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":11517000000.0,"depreciationAndCashflowFromOperatingActivities":3943000000.0,"cashFlowFromInvestingActivities":-3138000000.0,"cashFlowFromFinancialActivities":-3992000000.0,"changesInCashAndCashEquivalents":4452000000.0,"列1":"q2r","submitDate":"2019\/11\/12","stockCode":4553,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.521,"cashAndCashEquivalents":null,"assets":193423000000.0,"currentAssets":112887000000.0,"fixedAsset":80535000000.0,"tangibleFixedAssets":72035000000.0,"intangibleFixedAssets":1156000000.0,"investmentAndOtherAssets":7342000000.0,"liabilities":92685000000.0,"currentLiabilities":38059000000.0,"shorTermDept":1250000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":7062000000.0,"fixedLiabilities":54625000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":38224000000.0,"netAsset":100737000000.0,"capitalStock":100585000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":93636000000.0,"treasuryStock":-5640000000.0,"valuationAndConversionAdjustments":152000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":84405000000.0,"costOfSales":45300000000.0,"grossProfit":39105000000.0,"sgaExpenses":24983000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":14122000000.0,"nonOperatingIncome":1422000000.0,"nonOperatingExpenses":114000000.0,"interestExpense":95000000.0,"ordinaryProfit":15430000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":1000000.0,"incomeBeforeTax":15429000000.0,"incomeTaxes":4459000000.0,"netIncome":10969000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10969000000.0,"comprehensiveIncome":11033000000.0,"eps":222.92,"dilutedEps":206.19,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/13","stockCode":4553,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":3325.0,"averageTemporaryStaff":666.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":29385000.0,"sharesOwendPercent":0.597,"outstandingShares":null,"numberOfSubsidiary":11.0,"bps":2126.42,"equityRatio":0.459,"cashAndCashEquivalents":18713000000.0,"assets":228138000000.0,"currentAssets":120375000000.0,"fixedAsset":107763000000.0,"tangibleFixedAssets":79330000000.0,"intangibleFixedAssets":17650000000.0,"investmentAndOtherAssets":10783000000.0,"liabilities":123489000000.0,"currentLiabilities":69468000000.0,"shorTermDept":21368000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6767000000.0,"fixedLiabilities":54020000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":36640000000.0,"netAsset":104649000000.0,"capitalStock":104132000000.0,"capital":4717000000.0,"capitalSurplus":7870000000.0,"accumulatedEarnings":97171000000.0,"treasuryStock":-5627000000.0,"valuationAndConversionAdjustments":517000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":110384000000.0,"costOfSales":59738000000.0,"grossProfit":50646000000.0,"sgaExpenses":34503000000.0,"salaryAndBenefit":10072000000.0,"depreciationAndSGA":null,"RDExpenses":8566000000.0,"operatingIncome":16143000000.0,"nonOperatingIncome":5031000000.0,"nonOperatingExpenses":184000000.0,"interestExpense":131000000.0,"ordinaryProfit":20990000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":281000000.0,"incomeBeforeTax":20709000000.0,"incomeTaxes":6206000000.0,"netIncome":14503000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":14503000000.0,"comprehensiveIncome":14933000000.0,"eps":294.74,"dilutedEps":272.62,"dividendPerShare":null,"per":7.69,"roe":0.148,"cashFlowFromOperatingActivities":19164000000.0,"depreciationAndCashflowFromOperatingActivities":8285000000.0,"cashFlowFromInvestingActivities":-39541000000.0,"cashFlowFromFinancialActivities":11748000000.0,"changesInCashAndCashEquivalents":-7938000000.0,"列1":"asr","submitDate":"2020\/6\/25","stockCode":4553,"accountingYear":"第64期（自　2019年4月1日　至　2020年3月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.432,"cashAndCashEquivalents":null,"assets":245145000000.0,"currentAssets":140165000000.0,"fixedAsset":104980000000.0,"tangibleFixedAssets":81778000000.0,"intangibleFixedAssets":16989000000.0,"investmentAndOtherAssets":6211000000.0,"liabilities":139197000000.0,"currentLiabilities":77352000000.0,"shorTermDept":21250000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6767000000.0,"fixedLiabilities":61844000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":55275000000.0,"netAsset":105948000000.0,"capitalStock":106014000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":99089000000.0,"treasuryStock":-5627000000.0,"valuationAndConversionAdjustments":-66000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":37900000000.0,"costOfSales":22003000000.0,"grossProfit":15896000000.0,"sgaExpenses":11325000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":4570000000.0,"nonOperatingIncome":538000000.0,"nonOperatingExpenses":329000000.0,"interestExpense":43000000.0,"ordinaryProfit":4778000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":7000000.0,"incomeBeforeTax":4772000000.0,"incomeTaxes":1436000000.0,"netIncome":3335000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3335000000.0,"comprehensiveIncome":2751000000.0,"eps":67.77,"dilutedEps":62.66,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/14","stockCode":4553,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":29920000.0,"sharesOwendPercent":0.6079,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.459,"cashAndCashEquivalents":25217000000.0,"assets":237406000000.0,"currentAssets":132933000000.0,"fixedAsset":104472000000.0,"tangibleFixedAssets":81279000000.0,"intangibleFixedAssets":16650000000.0,"investmentAndOtherAssets":6542000000.0,"liabilities":128377000000.0,"currentLiabilities":68159000000.0,"shorTermDept":21216000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6369000000.0,"fixedLiabilities":60218000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":53764000000.0,"netAsset":109029000000.0,"capitalStock":108930000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":102005000000.0,"treasuryStock":-5626000000.0,"valuationAndConversionAdjustments":98000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":74640000000.0,"costOfSales":43313000000.0,"grossProfit":31327000000.0,"sgaExpenses":22544000000.0,"salaryAndBenefit":6297000000.0,"depreciationAndSGA":null,"RDExpenses":4589000000.0,"operatingIncome":8782000000.0,"nonOperatingIncome":539000000.0,"nonOperatingExpenses":594000000.0,"interestExpense":94000000.0,"ordinaryProfit":8727000000.0,"extraordinaryGain":79000000.0,"extraordinaryLoss":151000000.0,"incomeBeforeTax":8655000000.0,"incomeTaxes":2404000000.0,"netIncome":6251000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6251000000.0,"comprehensiveIncome":5831000000.0,"eps":127.02,"dilutedEps":123.97,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":5524000000.0,"depreciationAndCashflowFromOperatingActivities":4865000000.0,"cashFlowFromInvestingActivities":-3881000000.0,"cashFlowFromFinancialActivities":4467000000.0,"changesInCashAndCashEquivalents":6156000000.0,"列1":"q2r","submitDate":"2020\/11\/13","stockCode":4553,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.47,"cashAndCashEquivalents":null,"assets":237673000000.0,"currentAssets":131812000000.0,"fixedAsset":105860000000.0,"tangibleFixedAssets":84234000000.0,"intangibleFixedAssets":14732000000.0,"investmentAndOtherAssets":6894000000.0,"liabilities":125932000000.0,"currentLiabilities":66148000000.0,"shorTermDept":21364000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6552000000.0,"fixedLiabilities":59784000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":52171000000.0,"netAsset":111740000000.0,"capitalStock":111044000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":104118000000.0,"treasuryStock":-5626000000.0,"valuationAndConversionAdjustments":696000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":115251000000.0,"costOfSales":67164000000.0,"grossProfit":48086000000.0,"sgaExpenses":33300000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":14786000000.0,"nonOperatingIncome":816000000.0,"nonOperatingExpenses":2557000000.0,"interestExpense":139000000.0,"ordinaryProfit":13045000000.0,"extraordinaryGain":106000000.0,"extraordinaryLoss":169000000.0,"incomeBeforeTax":12982000000.0,"incomeTaxes":3535000000.0,"netIncome":9447000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9447000000.0,"comprehensiveIncome":9610000000.0,"eps":191.96,"dilutedEps":187.48,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4553,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":3456.0,"averageTemporaryStaff":684.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":30639000.0,"sharesOwendPercent":0.6225,"outstandingShares":null,"numberOfSubsidiary":11.0,"bps":2369.21,"equityRatio":0.475,"cashAndCashEquivalents":22915000000.0,"assets":245668000000.0,"currentAssets":137290000000.0,"fixedAsset":108378000000.0,"tangibleFixedAssets":85898000000.0,"intangibleFixedAssets":14963000000.0,"investmentAndOtherAssets":7516000000.0,"liabilities":129069000000.0,"currentLiabilities":51516000000.0,"shorTermDept":1111000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":7181000000.0,"fixedLiabilities":77552000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":69945000000.0,"netAsset":116599000000.0,"capitalStock":115554000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":108629000000.0,"treasuryStock":-5626000000.0,"valuationAndConversionAdjustments":1044000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":154900000000.0,"costOfSales":89448000000.0,"grossProfit":65451000000.0,"sgaExpenses":45527000000.0,"salaryAndBenefit":12477000000.0,"depreciationAndSGA":null,"RDExpenses":10642000000.0,"operatingIncome":19923000000.0,"nonOperatingIncome":1488000000.0,"nonOperatingExpenses":2734000000.0,"interestExpense":190000000.0,"ordinaryProfit":18677000000.0,"extraordinaryGain":245000000.0,"extraordinaryLoss":194000000.0,"incomeBeforeTax":18728000000.0,"incomeTaxes":4770000000.0,"netIncome":13958000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":13958000000.0,"comprehensiveIncome":14469000000.0,"eps":283.62,"dilutedEps":271.93,"dividendPerShare":null,"per":8.61,"roe":0.126,"cashFlowFromOperatingActivities":12008000000.0,"depreciationAndCashflowFromOperatingActivities":9674000000.0,"cashFlowFromInvestingActivities":-9100000000.0,"cashFlowFromFinancialActivities":184000000.0,"changesInCashAndCashEquivalents":3855000000.0,"列1":"asr","submitDate":"2021\/6\/28","stockCode":4553,"accountingYear":"第65期（自　2020年4月1日　至　2021年3月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.49,"cashAndCashEquivalents":null,"assets":249189000000.0,"currentAssets":140224000000.0,"fixedAsset":108964000000.0,"tangibleFixedAssets":86036000000.0,"intangibleFixedAssets":15251000000.0,"investmentAndOtherAssets":7676000000.0,"liabilities":127074000000.0,"currentLiabilities":51327000000.0,"shorTermDept":1269000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":7481000000.0,"fixedLiabilities":75746000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":68152000000.0,"netAsset":122114000000.0,"capitalStock":119783000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":112857000000.0,"treasuryStock":-5626000000.0,"valuationAndConversionAdjustments":2331000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":42927000000.0,"costOfSales":24679000000.0,"grossProfit":18248000000.0,"sgaExpenses":12166000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":6081000000.0,"nonOperatingIncome":1695000000.0,"nonOperatingExpenses":61000000.0,"interestExpense":53000000.0,"ordinaryProfit":7715000000.0,"extraordinaryGain":58000000.0,"extraordinaryLoss":60000000.0,"incomeBeforeTax":7714000000.0,"incomeTaxes":2402000000.0,"netIncome":5311000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":5311000000.0,"comprehensiveIncome":6597000000.0,"eps":107.92,"dilutedEps":105.53,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/13","stockCode":4553,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":32610000.0,"sharesOwendPercent":0.6626,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.5,"cashAndCashEquivalents":24389000000.0,"assets":252906000000.0,"currentAssets":141548000000.0,"fixedAsset":111357000000.0,"tangibleFixedAssets":87332000000.0,"intangibleFixedAssets":15624000000.0,"investmentAndOtherAssets":8401000000.0,"liabilities":126495000000.0,"currentLiabilities":56748000000.0,"shorTermDept":1300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":7978000000.0,"fixedLiabilities":69747000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":66247000000.0,"netAsset":126410000000.0,"capitalStock":123714000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":116788000000.0,"treasuryStock":-5626000000.0,"valuationAndConversionAdjustments":2696000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":82254000000.0,"costOfSales":46876000000.0,"grossProfit":35378000000.0,"sgaExpenses":25066000000.0,"salaryAndBenefit":6942000000.0,"depreciationAndSGA":null,"RDExpenses":5654000000.0,"operatingIncome":10312000000.0,"nonOperatingIncome":2814000000.0,"nonOperatingExpenses":118000000.0,"interestExpense":107000000.0,"ordinaryProfit":13008000000.0,"extraordinaryGain":94000000.0,"extraordinaryLoss":60000000.0,"incomeBeforeTax":13043000000.0,"incomeTaxes":3800000000.0,"netIncome":9242000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9242000000.0,"comprehensiveIncome":10893000000.0,"eps":187.79,"dilutedEps":183.63,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":14301000000.0,"depreciationAndCashflowFromOperatingActivities":4811000000.0,"cashFlowFromInvestingActivities":-9334000000.0,"cashFlowFromFinancialActivities":-3749000000.0,"changesInCashAndCashEquivalents":1473000000.0,"列1":"q2r","submitDate":"2021\/11\/12","stockCode":4553,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00974","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.51,"cashAndCashEquivalents":null,"assets":256033000000.0,"currentAssets":144641000000.0,"fixedAsset":111391000000.0,"tangibleFixedAssets":87698000000.0,"intangibleFixedAssets":15938000000.0,"investmentAndOtherAssets":7754000000.0,"liabilities":125369000000.0,"currentLiabilities":57434000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":7553000000.0,"fixedLiabilities":67935000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":64617000000.0,"netAsset":130663000000.0,"capitalStock":128143000000.0,"capital":4717000000.0,"capitalSurplus":7834000000.0,"accumulatedEarnings":121218000000.0,"treasuryStock":-5626000000.0,"valuationAndConversionAdjustments":2519000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":125613000000.0,"costOfSales":71847000000.0,"grossProfit":53766000000.0,"sgaExpenses":36772000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":16993000000.0,"nonOperatingIncome":4250000000.0,"nonOperatingExpenses":184000000.0,"interestExpense":156000000.0,"ordinaryProfit":21059000000.0,"extraordinaryGain":134000000.0,"extraordinaryLoss":70000000.0,"incomeBeforeTax":21123000000.0,"incomeTaxes":6122000000.0,"netIncome":15000000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":15000000000.0,"comprehensiveIncome":16475000000.0,"eps":304.8,"dilutedEps":298.05,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/14","stockCode":4553,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00974","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4717,"settlementDate":"2022\/3\/31","submitterName":"東和薬品株式会社","submitterNameEnglish":"TOWA PHARMACEUTICAL CO.,LTD.","submitterNameKana":"トウワヤクヒンカブシキガイシャ","location":"門真市新橋町２番１１号","industory":"医薬品","corporateNumber":4120000000000.0}]